


CLAIMS

1. A compound having the formula (I),




5 a N-oxide form, stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof,

wherein

A is aryl, heteroaryl or heterocycloalkyl;

R¹ represents hydrogen, halogen, hydroxy, amino, nitro, alkyl, alkyloxy, or a radical of
10 formula (II),



R² represents alkyl, alkenyl, alkynyl, hydroxy, halogen, nitro, cyano, amino, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, R⁸-O-, R⁸-S-, R⁸-S(=O)₂-, R⁸-C(=O)-, R⁸-C(=S)-, R⁸-C(=NH)-, R⁸-C(=NCN)-, R⁸-NH-, (R⁸)₂-N-, HO-C(=O)-, NH₂-C(=O)-, NH₂-S(=O)₂-, NH₂-C(=S)-, NH₂-C(=NH)-, NH₂-C(=NCN)-, R⁸-NR⁴-C(=O)-, R⁸-NR⁴-S(=O)₂-, R⁸-O-C(=O)-, R⁸-C(=O)-NR⁴-, R⁸-S(=O)₂-NR⁴-, R⁸-C(=O)-O-, R⁸-S-CH₂- or R⁸-O-CH₂-C(=O)-;

R³ represents hydroxy, amino, alkyloxy, cycloalkyloxy or mono- or disubstituted amino whereby the substituents can be selected from alkyl and cycloalkyl;

20 R⁴ represents hydrogen, alkyl or cycloalkyl;

R⁶ is hydrogen, amino, R⁷-C(=O)-, R⁸-S(=O)₂-NH-, R⁸-C(=O)-NH-, R⁸-C(=S)-NH-, R⁸-C(=NH)-NH-, R⁸-C(=NCN)-NH-, R⁸-O-C(=O)-NH-, R⁸-O-alkanediyl-C(=O)-NH-, R⁸-alkanediyl-S(=O)₂-NH-, aryl-alkanediyl-C(=O)-NH-, aryl-alkenediyl-C(=O)-NH-, heteroaryl-alkanediyl-C(=O)-NH-, cycloalkyl-alkanediyl-C(=O)-NH-,

25 heterocycloalkyl-alkanediyl-C(=O)-NH- or substituted alkyl whereby the substituents can be selected from amino, R⁷-C(=O)-, R⁸-S(=O)₂-NH-, R⁸-C(=O)-NH-, R⁸-C(=S)-NH-, R⁸-C(=NH)-NH-, R⁸-C(=NCN)-NH-, R⁸-O-C(=O)-NH-, R⁸-O-alkanediyl-C(=O)-NH-, R⁸-alkanediyl-S(=O)₂-NH-, aryl-alkanediyl-C(=O)-NH-, heteroaryl-alkanediyl-C(=O)-NH-,

cycloalkyl-alkanediyl-C(=O)-NH- and heterocycloalkyl-alkanediyl-C(=O)-NH-;

R^7 represents hydroxy, amino, alkyloxy, cycloalkyloxy or mono- or disubstituted amino whereby the substituents can be selected from alkyl and cycloalkyl;

R^8 represents alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl;


- 5 Y represents alkanediyl, -C(=O)-, -C(=S)-, -C(=NH)-, -C(=NCN)-, -S(=O)-, -S(=O)₂-, -C(=O)-CH₂-O-, -C(=O)-O-, -C(=O)-(CH₂)_p-, -C(=O)-NH- or -alkenediyl-C(=O)-;

X is a direct bond, -O-, -S-, -S(=O)₂-, -O-S(=O)₂-, -S(=O)₂-O-, -NH-S(=O)₂-, -S(=O)₂-NH-, -C(=O)-, -C(=S)-, -C(=NH)-, -C(=NCN)-, -O-C(=O)-, -C(=O)-O-, -NH-C(=O)-, -C(=O)-NH- or alkanediyl;

- 10 m and n are each independently zero, one or two;


p is an integer from 1 to 4;

2. A compound having the formula (III),



- 15 a N-oxide form, a stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof, wherein

R^1 represents halogen, hydrogen or a radical of formula (II),



- 20 R^2 represents alkyl, alkenyl, alkynyl, hydroxy, halogen, nitro, cyano, amino, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, R^8 -O-, R^8 -S-, R^8 -S(=O)₂-, R^8 -C(=O)-, R^8 -C(=S)-, R^8 -C(=NH)-, R^8 -C(=NCN)-, R^8 -NH-, (R^8)₂-N-, HO-C(=O)-, NH₂-C(=O)-, NH₂-S(=O)₂-, NH₂-C(=S)-, NH₂-C(=NH)-, NH₂-C(=NCN)-, R^8 -NR⁴-C(=O)-, R^8 -NR⁴-S(=O)₂-, R^8 -O-C(=O)-, R^8 -C(=O)-NR⁴-, R^8 -S(=O)₂-NR⁴- or R^8 -C(=O)-O-;

- 25 R^3 represents hydroxy, amino, alkyloxy, cycloalkyloxy or mono- or disubstituted amino whereby the substituents can be selected from alkyl and cycloalkyl;


R^4 represents hydrogen, alkyl or cycloalkyl;

- R^6 is hydrogen, amino, $R^7-C(=O)-$, $R^8-S(=O)_2-NH-$, $R^8-C(=O)-NH-$, $R^8-C(=S)-NH-$, $R^8-C(=NH)-NH-$, $R^8-C(=NCN)-NH-$, $R^8-O-C(=O)-NH-$, R^8-O -alkanediyl- $C(=O)-NH-$, R^8 -alkanediyl- $S(=O)_2-NH-$, aryl-alkanediyl- $C(=O)-NH-$, heteroaryl-alkanediyl- $C(=O)-NH-$, cycloalkyl-alkanediyl- $C(=O)-NH-$,
5 heterocycloalkyl-alkanediyl- $C(=O)-NH-$ or substituted alkyl whereby the substituents can be selected from amino, $R^7-C(=O)-$, $R^8-S(=O)_2-NH-$, $R^8-C(=O)-NH-$, $R^8-C(=S)-NH-$, $R^8-C(=NH)-NH-$, $R^8-C(=NCN)-NH-$, $R^8-O-C(=O)-NH-$, R^8-O -alkanediyl- $C(=O)-NH-$, R^8 -alkanediyl- $S(=O)_2-NH-$, aryl-alkanediyl- $C(=O)-NH-$, heteroaryl-alkanediyl- $C(=O)-NH-$,
10 cycloalkyl-alkanediyl- $C(=O)-NH-$ and heterocycloalkyl-alkanediyl- $C(=O)-NH-$;
 R^7 represents hydroxy, amino, alkyloxy, cycloalkyloxy or mono- or disubstituted amino whereby the substituents can be selected from alkyl and cycloalkyl;
 R^8 represents alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl;
Y represents alkanediyl, $-C(=O)-$, $-C(=S)-$, $-C(=NH)-$, $-C(=NCN)-$, $-S(=O)-$, $-S(=O)_2-$,
15 $-C(=O)-CH_2-O-$, $-C(=O)-O-$, $-C(=O)-(CH_2)_p-$;
X is a direct bond, $-O-$, $-S-$, $-S(=O)_2-$, $-O-S(=O)_2-$, $-S(=O)_2-O-$, $-NH-S(=O)_2-$, $-S(=O)_2-NH-$, $-C(=O)-$, $-C(=S)-$, $-C(=NH)-$, $-C(=NCN)-$, $-O-C(=O)-$, $-C(=O)-O-$, $-NH-C(=O)-$, $-C(=O)-NH-$ or alkanediyl;
m and n are each independently zero, one or two;
20 p is an integer from 1 to 4;

3. A compound as claimed in claim 1 or 2 and wherein Y is $-C(=O)-$, $-S(=O)_2-$.
4. A compound as claimed in claim 1 or 2 and wherein X is a $-NH-S(=O)_2-$,
25 $-S(=O)_2-NH-$, $-NH-C(=O)-$, $-C(=O)-NH-$.
5. A compound as claimed in claim 1 or 2 and wherein R^2 is halogen, bromo, chloro, alkyl, alkyloxy haloalkyl, alkenyl, alkynyl, said substituents in meta or para position; and n is 1.

30

6. A compound as claimed in claim 1 or 2 and wherein R^1 is formula (II),



- R^6 is $R^7-C(=O)-$, $R^8-S(=O)_2-NH-$, $R^8-C(=O)-NH-$, said substituents R^6 are adjacent; in
35 meta and para position, or in ortho and meta position;

m is 2,

R⁷ is hydroxy, alkyloxy;

R⁸ is aryl substituted with one halogen, bromo, chloro alkyl, alkyloxy haloalkyl, alkenyl, alkynyl, said substituents in meta or para position.

5

7. A compound as claimed in any one of claims 1 to 6, wherein compound is a monomer.

8. A compound as claimed in any one of claims 1 to 6, wherein compound is a dimer.

10

9. A compound as claimed in any one of claims 1 to 8 for use as a medicine.

10. The use of a compound as claimed in any one of claims 1 to 8 for the manufacture of a medicament capable of inhibiting the entry process of the HIV virus into a

15

mammalian host cell.

11. A pharmaceutical composition containing a therapeutically effective amount of an active ingredient as claimed in any one of claims 1 to 8 and one or more pharmaceutically acceptable excipients.

20